Table 2 The relation between RUNX2 (protein and RNA) expressions and the clinicopathological features of the patients
Clinical features | RUNX2 expression | |||
|---|---|---|---|---|
RUNX2 protein expression (72/80) | RUNX2 -RNA expression (60/80) | |||
No. (%) | P value | No. (%) | P value | |
Gender | ||||
 Males (52) | 48 (92.3) |  | 44 (84.6) |  |
 Females (28) | 24 (85.7) | 0.348 | 16 (57.1) | 0.007 |
Age (median) | ||||
  < 21 years (40) | 40 (100) |  | 32 (80) |  |
  ≥ 21 years (40) | 32 (80) | 0.005 | 28 (70) | 0.302 |
Site | ||||
 Femur (48) | 44 (91.7) |  | 36 (75) |  |
 Tibia (20) | 16 (80) |  | 12 (60) |  |
 Humerus (12) | 12 (100) | 0.232 | 12 (100) | 0.041 |
Tumor Grade | ||||
 2 (16) | 8 (50) |  | 4 (25) |  |
 3 (64) | 64 (100) | <0.001* | 56 (87.5) | <0.001* |
pTNM Stage | ||||
 I, II (44) | 36 (81.8) |  | 24 (54.5) |  |
 III, IV (36) | 36 (100) | 0.007 | 36 (100) | <0.001* |
Metastasis | ||||
 Present (20) | 20 (100) |  | 20 (100) |  |
 Absent (60) | 52 (86.7) | 0.085$ | 40 (66.7) | 0.003 |